Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10427470 | 0.95 | NPC1 (0.47) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL5585822 | 0.78 | NPC1 (0.51) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL12336002 | 0.78 | PTGS2 (0.53) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL5932198 | 0.77 | HDAC2 (0.44) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL27797782 | 0.76 | RAB9A (0.57) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL5932189 | 0.74 | HDAC2 (0.44) | NPC1RAB9ASMN1; SMN2NFKB1HTT | |
| SCHEMBL12757508 | 0.72 | SERPINE1 (0.52) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL14099881 | 0.72 | NPC1 (0.50) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL25095364 | 0.72 | HDAC2 (0.42) | NPC1RAB9ASMN1; SMN2NFKB1HTT | |
| SCHEMBL5932684 | 0.72 | HDAC2 (0.42) | NPC1RAB9ASMN1; SMN2NFKB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326700-B2 | Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2008-02-05 | — | — | US | disclosed |
| US-6903087-B2 | For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, PRLHR | NPC1 4637/4885RAB9A 4783/4885TP53 4728/4885 |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | NPC1 4166/4885RAB9A 4755/4885TP53 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.